114 related articles for article (PubMed ID: 17433911)
1. Mutant transcription factors and tyrosine kinases as therapeutic targets for leukemias: from acute promyelocytic leukemia to chronic myeloid leukemia and beyond.
Hu J; Zhou GB; Wang ZY; Chen SJ; Chen Z
Adv Cancer Res; 2007; 98():191-220. PubMed ID: 17433911
[TBL] [Abstract][Full Text] [Related]
2. Molecular targets and the treatment of myeloid leukemia.
Ikeda A; Shankar DB; Watanabe M; Tamanoi F; Moore TB; Sakamoto KM
Mol Genet Metab; 2006 Jul; 88(3):216-24. PubMed ID: 16678459
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
[TBL] [Abstract][Full Text] [Related]
4. From dissection of disease pathogenesis to elucidation of mechanisms of targeted therapies: leukemia research in the genomic era.
Zhou GB; Li G; Chen SJ; Chen Z
Acta Pharmacol Sin; 2007 Sep; 28(9):1434-49. PubMed ID: 17723177
[TBL] [Abstract][Full Text] [Related]
5. Retinoic acid receptors, hematopoiesis and leukemogenesis.
Collins SJ
Curr Opin Hematol; 2008 Jul; 15(4):346-51. PubMed ID: 18536573
[TBL] [Abstract][Full Text] [Related]
6. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
Chien JH; Tang JL; Chen RL; Li CC; Lee CP
Leuk Res; 2008 Nov; 32(11):1724-34. PubMed ID: 18603297
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
8. [Molecular hemato-oncology and new specific treatment strategies for leukemia].
Martínez-Mancilla M; Zafra-de la Rosa G; Reynoso-Gómez E; Astudillo-de la Vega H; Nambo-Lucio Mde J; Benítez-Bribiesca L; Martínez-Avalos A; Rivera-Luna R; Gariglio P
Gac Med Mex; 2006; 142(2):145-50. PubMed ID: 16711549
[TBL] [Abstract][Full Text] [Related]
9. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
10. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
11. Reduction of BCR-ABL1 mutant clones after discontinuation of TKI therapy.
Beel K; Janssens A; Verhoef G; Vandenberghe P
Leuk Res; 2009 Dec; 33(12):1703-5. PubMed ID: 19457553
[TBL] [Abstract][Full Text] [Related]
12. Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib.
Ernst T; Erben P; Müller MC; Paschka P; Schenk T; Hoffmann J; Kreil S; La Rosée P; Hehlmann R; Hochhaus A
Haematologica; 2008 Feb; 93(2):186-92. PubMed ID: 18223278
[TBL] [Abstract][Full Text] [Related]
13. Promyelocytic blast crisis of chronic myeloid leukemia during imatinib treatment.
Chung HJ; Chi HS; Cho YU; Park CJ; Seo EJ; Kim KH; Lee JH
Ann Clin Lab Sci; 2008; 38(3):283-6. PubMed ID: 18715859
[TBL] [Abstract][Full Text] [Related]
14. [Detection of ABL kinase domain point mutations in chronic myeloid leukemia patients receiving imatinib treatment].
Ouyang Z; DU QF; Liu XL; Zhang S; Zhu HQ; Gong JM; Song LL; Ouyang LY; Liu Z
Nan Fang Yi Ke Da Xue Xue Bao; 2008 May; 28(5):704-6. PubMed ID: 18504184
[TBL] [Abstract][Full Text] [Related]
15. Flying under the radar: the new wave of BCR-ABL inhibitors.
Quintás-Cardama A; Kantarjian H; Cortes J
Nat Rev Drug Discov; 2007 Oct; 6(10):834-48. PubMed ID: 17853901
[TBL] [Abstract][Full Text] [Related]
16. Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia.
Kuroda J; Kimura S; Strasser A; Andreeff M; O'Reilly LA; Ashihara E; Kamitsuji Y; Yokota A; Kawata E; Takeuchi M; Tanaka R; Tabe Y; Taniwaki M; Maekawa T
Cell Death Differ; 2007 Sep; 14(9):1667-77. PubMed ID: 17510658
[TBL] [Abstract][Full Text] [Related]
17. Roots of imatinib resistance: a question of self-renewal?
Burchert A
Drug Resist Updat; 2007; 10(4-5):152-61. PubMed ID: 17683977
[TBL] [Abstract][Full Text] [Related]
18. Imatinib mesylate therapy in chronic myeloid leukaemia: the floodgates opened.
Agarwal MB
J Assoc Physicians India; 2007 Feb; 55():99-100. PubMed ID: 17571737
[No Abstract] [Full Text] [Related]
19. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
Rahmani M; Nguyen TK; Dent P; Grant S
Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
[TBL] [Abstract][Full Text] [Related]
20. Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.
Giles FJ; DeAngelo DJ; Baccarani M; Deininger M; Guilhot F; Hughes T; Mauro M; Radich J; Ottmann O; Cortes J
Semin Oncol; 2008 Feb; 35(1 Suppl 1):S1-17; quiz S18-20. PubMed ID: 18346528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
